Spots Global Cancer Trial Database for pembrolizumab injection
Every month we try and update this database with for pembrolizumab injection cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma | NCT04435197 | Esophageal Squa... | Pembrolizumab I... | 18 Years - 75 Years | Ruijin Hospital | |
| Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) | NCT03391973 | Carcinoma of Un... | Pembrolizumab I... | 18 Years - | AHS Cancer Control Alberta | |
| Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) | NCT03391973 | Carcinoma of Un... | Pembrolizumab I... | 18 Years - | AHS Cancer Control Alberta | |
| Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab | NCT05075122 | Head and Neck S... | UV1 Sargramostim fo... Pembrolizumab i... | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) | NCT06005818 | Renal Cell Carc... | Pembrolizumab i... | 18 Years - | University of Alabama at Birmingham | |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | NCT04387461 | Non Muscle Inva... | CG0070 Pembrolizumab I... n-dodecyl-B-D-m... | 18 Years - | CG Oncology, Inc. | |
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) | NCT04964479 | Non Small Cell ... | TQB2450 injecti... Anlotinib Hydro... Pembrolizumab i... Placebo | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NCT05877430 | NSCLC HNSCC Melanoma Metastatic Canc... Advanced Solid ... Advanced Cancer | CJRB-101 Pembrolizumab i... | 18 Years - | CJ Bioscience, Inc. | |
| Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors | NCT05307874 | Solid Tumor, Ad... | ICT01 Proleukin Injec... Pembrolizumab i... | 18 Years - | ImCheck Therapeutics | |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | NCT03515798 | Inflammatory Br... | Pembrolizumab I... neoadjuvant EC-... | 18 Years - | Institut Paoli-Calmettes | |
| Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab | NCT05075122 | Head and Neck S... | UV1 Sargramostim fo... Pembrolizumab i... | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) | NCT04808999 | Squamous Cell C... | Pembrolizumab I... | 18 Years - | University of Pittsburgh | |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic Squamous NSCLC Patients | NCT05899608 | Non-Small Cell ... | Ivonescimab Inj... Pembrolizumab I... | 18 Years - | Summit Therapeutics | |
| Development and Analysis of a Stool Bank for Cancer Patients | NCT04291755 | Carcinoma, Non-... Carcinoma, Colo... | Pembrolizumab I... | 18 Years - | Persephone Biosciences | |
| Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX | NCT03134456 | Metastatic Non-... | Pembrolizumab I... | 18 Years - | Samsung Medical Center | |
| Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab | NCT06371807 | Early Breast Ca... Triple Negative... | Pembrolizumab i... | 18 Years - 100 Years | Fundacao Champalimaud | |
| Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | NCT04089904 | Gastroesophagea... Gastric Adenoca... Esophageal Aden... | Pembrolizumab I... | 18 Years - | University of Chicago | |
| Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | NCT05973864 | Triple Negative... | Pembrolizumab i... Capecitabine ta... Local radiother... | 18 Years - | UNICANCER | |
| Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors | NCT05307874 | Solid Tumor, Ad... | ICT01 Proleukin Injec... Pembrolizumab i... | 18 Years - | ImCheck Therapeutics | |
| Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | NCT04089904 | Gastroesophagea... Gastric Adenoca... Esophageal Aden... | Pembrolizumab I... | 18 Years - | University of Chicago | |
| Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab | NCT05075122 | Head and Neck S... | UV1 Sargramostim fo... Pembrolizumab i... | 18 Years - | Martin-Luther-Universität Halle-Wittenberg | |
| A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | NCT05746897 | Ovarian Cancer Melanoma Triple Negative... Colorectal Canc... | NM1F Injection Pembrolizumab i... | 18 Years - | Hefei TG ImmunoPharma Co., Ltd. | |
| Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers | NCT03193931 | Cancer of Head ... | Pembrolizumab I... Methotrexate In... | 18 Years - | AIO-Studien-gGmbH | |
| Phase II Trial of Neoadjuvant Pembrolizumab for Patients With Early Stage Gastroesophageal Adenocarcinoma | NCT04089904 | Gastroesophagea... Gastric Adenoca... Esophageal Aden... | Pembrolizumab I... | 18 Years - | University of Chicago | |
| Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) | NCT04808999 | Squamous Cell C... | Pembrolizumab I... | 18 Years - | University of Pittsburgh | |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin | NCT04387461 | Non Muscle Inva... | CG0070 Pembrolizumab I... n-dodecyl-B-D-m... | 18 Years - | CG Oncology, Inc. | |
| Development and Analysis of a Stool Bank for Cancer Patients | NCT04291755 | Carcinoma, Non-... Carcinoma, Colo... | Pembrolizumab I... | 18 Years - | Persephone Biosciences | |
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) | NCT04964479 | Non Small Cell ... | TQB2450 injecti... Anlotinib Hydro... Pembrolizumab i... Placebo | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | NCT05877430 | NSCLC HNSCC Melanoma Metastatic Canc... Advanced Solid ... Advanced Cancer | CJRB-101 Pembrolizumab i... | 18 Years - | CJ Bioscience, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
